Please login to the form below

Not currently logged in
Email:
Password:

Apeiron bolsters management board

Peter Llewellyn-Davies joins as its CFO and CBO

Van De WinkelViennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter Llewellyn-Davies.

With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ran his own consulting firm Accellerate Partners.

He said: “Apeiron is currently amongst the most compelling privately owned European biotech companies and I am looking forward to working together with the team to jointly lead Apeiron through the next phase of growth.”

During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.

Dr Hans Loibner, chief executive officer, Apeiron, said: “Peter’s expertise, which has been proven by many international capital market transactions, is highly welcome, and he is an ideal addition to support our growth strategy.

“I very much look forward to working hand in hand with him.”

7th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics